BSc (Hons), PhD
Professor of Metabolic Physiology
- BHF Senior Basic Science Research Fellow
Integrative Physiology (Systems Biology)
I am heading the Metabolic Research Group together with Professor Fredrik Karpe. My research focuses on the alterations in metabolism with nutritional state and substrates (e.g. sugars, fatty acids) along with the associated metabolic consequences of obesity. We perform whole body human physiological studies to understand the metabolic integration between tissues.
The current focus of my research is on understanding liver fat metabolism, as perturbations in this have the potential to impact widely on metabolic health. Accumulation of fat within the liver underlies the spectrum of conditions known as non-alcoholic fatty liver disease (NAFLD) and this is a risk factor for cardiovascular disease and diabetes. The liver is a major player in fat metabolism; it integrates endogenous and exogenous fatty acids and the accumulation or loss of liver fat represents the balance between input and removal pathways. However, the regulation of the metabolic partitioning of fatty acids within the human liver is poorly understood. We use a combination of approaches, including human in vivo, ex vivo, and in vitro cellular models along metabolically-labelled substrates (stable-isotope tracers) to probe relevant pathways involved liver fat metabolism. By understanding the regulation of these pathways, this may lead to interesting new therapeutic approaches to prevent and/or treat NAFLD.
I was awarded a British Heart Foundation Senior Fellowship in Basic Science in 2015. Prior to this, I was awarded the Gridlers’ Health Research Council (NZ) Career Development Fellowship, which enabled me to come and undertake post-doctoral work at the University of Oxford in 2004 and I held a British Heart Foundation Intermediate Fellowship in Basic Science from 2011-2015.
Hepatocyte mARC1 promotes fatty liver disease
Lewis LC. et al, (2023), JHEP Reports, 5
MLX plays a key role in lipid and glucose metabolism in humans: evidence from in vitro and in vivo studies
NAGARAJAN S. et al, (2023), Metabolism: clinical and experimental
Nutritional regulation of hepatic de novo lipogenesis in humans.
Cross E. et al, (2023), Curr Opin Clin Nutr Metab Care, 26, 65 - 71
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Othonos N. et al, (2023), Nat Commun, 14
An optimised protocol for the investigation of insulin signalling in a human cell culture model of adipogenesis.
Gamwell JM. et al, (2023), Adipocyte